Meeting
2021 Genitourinary Cancers Symposium
Effectiveness of first-line immune checkpoint inhibitors (ICI) in advanced non-clear cell renal cell carcinoma (ccRCC).
Authors
Jeffrey Graham
University of Manitoba, Winnipeg, MB, Canada
Jeffrey Graham , Connor Wells , Shaan Dudani , Chun Loo Gan , Frede Donskov , Jae-Lyun Lee , Christian K. Kollmannsberger , Sumanta K. Pal , Benoit Beuselinck , Aaron Richard Hansen , Scott A. North , Georg A. Bjarnason , Neeraj Agarwal , Ravindran Kanesvaran , Lori Wood , Sebastien J. Hotte , Rana R. McKay , Toni K. Choueiri , Daniel Yick Chin Heng
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 316)
DOI
10.1200/JCO.2021.39.6_suppl.316
Abstract #
316
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Is there a benefit of immune checkpoint inhibitors for patients over 75 years of age with advanced cancer in first and second line setting: A meta-analysis.
First Author: Thierry Landre
Poster
2019 ASCO Annual Meeting
Phase 3 (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) versus sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy.
First Author: Robin Kate Kelley
Poster
2023 ASCO Annual Meeting
Time-dependent efficacy of immune checkpoint inhibitors in the treatment of metastatic cancers: A meta-analysis.
First Author: Thierry Landre
Poster
2023 ASCO Genitourinary Cancers Symposium
The survival outcomes of metastatic non-clear cell renal cell carcinoma in the immunotherapy era: Princess Margaret Cancer Centre (PMCC) experience.
First Author: Esmail Mutahar Al-Ezzi